Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS known ✓ | P04818 | 5/20 | 0.78 |
| ▸ | GART known ✓ | P22102 | 10/20 | 0.58 |
| ▸ | DHFR known ✓ | P00374 | 6/20 | 0.58 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.58 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.58 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.58 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.58 |
| ▸ | ATIC | P31939 | 2/20 | 0.58 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.58 |
| ▸ | FRK | P42685 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL1651788 | 1.00 | TYMS (0.78) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL5333210 | 1.00 | TYMS (0.78) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL2037608 | 0.99 | TYMS (0.77) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL21599244 | 0.99 | TYMS (0.77) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL1934530 | 0.99 | TYMS (0.77) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL135815 | 0.99 | TYMS (0.77) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL15649196 | 0.98 | TYMS (0.75) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL2268170 | 0.94 | TYMS (0.70) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL4987130 | 0.94 | TYMS (0.69) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL1271410 | 0.92 | TYMS (0.68) | TYMSGARTDHFRFOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22857 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-3212193-B1 | CRYSTALLINE FORMS OF PEMETREXED DIACID AND MANUFACTURING PROCESSES THEREFOR | SCINOPHARM TAIWAN LTD (TW) | 2026-04-15 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260027088-A1 | Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer | UNIV EMORY (US) | 2026-01-29 | — | — | US | claimed |
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | claimed |
| CN-1679950-A | Anticarcinogenic internal implant agent | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | claimed |
| CN-1491111-A | Antiviral method of use | — | 2004-04-21 | — | — | CN | claimed |
| US-20040067965-A1 | Antiviral method of use | BALOGH DOUGLAS WAYNE (US) | 2004-04-08 | — | — | US | claimed |
| EP-1377296-A2 | ANTIVIRAL METHOD OF USE | ELI LILLY AND COMPANY (US) | 2004-01-07 | — | — | EP | claimed |
| US-20030212038-A1 | Novel antifolate combination therapies | ELI LILLY AND COMPANY | 2003-11-13 | — | — | US | claimed |
| EP-1313508-A2 | COMBINATION CONTAINING AN ANTIFOLATE AND METHYLMALONIC ACID LOWERING AGENT | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | claimed |
| WO-2002101391-A2 | METHOD OF USE | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | claimed |
| WO-2002069950-A2 | TUMOR TREATEMENT WITH A COMBINATION OF A SUBSTRATE OF MRP5 AND MODULATORS OF MRP5 | ELI LILLY AND COMPANY (US) | 2002-09-12 | — | — | WO | claimed |
| WO-2002066037-A2 | ANTIVIRAL METHOD OF USE | ELI LILLY AND COMPANY (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2002002093-A2 | COMBINATION CONTAINING AN ANTIFOLATE AND METHYLMALONIC ACID LOWERING AGENT | ELI LILLY AND COMPANY (US) | 2002-01-10 | — | — | WO | claimed |